Phase I/II study of alectinib in lung cancer with RET fusion gene: Study protocol

Shinji Takeuchi, Toshinori Murayama, Kenichi Yoshimura, Takahiro Kawakami, Shizuko Takahara, Yasuhito Imai, Yoshikazu Kuribayashi, Katsuhiko Nagase, Koichi Goto, Makoto Nishio, Yoshinori Hasegawa, Miyako Satouchi, Katsuyuki Kiura, Takashi Seto, Seiji Yano

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Background: The rearranged during transfection (RET) fusion gene was discovered as a driver on-cogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. Methods/Design: RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design. The primary endpoint is safety. In step 2, alectinib will be administered at the recommended dose (RD) defined by step 1. The primary endpoint is the response rate of RET inhibitor treatment-naïve patients. Conclusion: This is the first study to investigate the safety and preliminary efficacy of alectinib in RET fusion-positive NSCLC patients. If successful, alectinib treatment may lead to substantial and important changes in the management of NSCLC with RET fusion genes.

Original languageEnglish
Pages (from-to)317-320
Number of pages4
JournalJournal of Medical Investigation
Issue number3-4
Publication statusPublished - 2017


  • Alectinib
  • Non-small cell lung cancer
  • RET fusion gene

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Phase I/II study of alectinib in lung cancer with RET fusion gene: Study protocol'. Together they form a unique fingerprint.

Cite this